SCHEMBL1007447

SCHEMBL1007447

NC(C(=O)O)[C@H](N)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 1/20 0.62
SLC1A3 P43003 5/20 0.50
SLC1A2 P43004 5/20 0.50
SLC1A1 P43005 5/20 0.50
USP2 O75604 1/20 0.46
SLCO1B1 Q9Y6L6 1/20 0.46
PTGS1 P23219 1/20 0.42
SLC7A11 Q9UPY5 1/20 0.42
GSR P00390 1/20 0.41
TSHR P16473 1/20 0.40
LMNA P02545 1/20 0.40
ALDH1A1 P00352 1/20 0.40
THRB P10828 1/20 0.40
RECQL P46063 1/20 0.40
ACHE P22303 1/20 0.39
GRM2 Q14416 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL468084 1.00 SLC7A5 (0.62) SLC7A5SLC1A3SLC1A2SLC1A1USP2
SCHEMBL29957453 1.00 SLC7A5 (0.62) SLC7A5SLC1A3SLC1A2SLC1A1USP2
SCHEMBL25933046 1.00 SLC7A5 (0.62) SLC7A5SLC1A3SLC1A2SLC1A1USP2
SCHEMBL600021 1.00 SLC7A5 (0.62) SLC7A5SLC1A3SLC1A2SLC1A1USP2
Hydrochloric Acid SCHEMBL11095114 0.96 SLC7A5 (0.59) SLC7A5SLC1A3SLC1A2SLC1A1USP2
SCHEMBL4632980 0.96 SLC7A5 (0.59) SLC7A5SLC1A3SLC1A2SLC1A1USP2
SCHEMBL4633860 0.96 SLC7A5 (0.59) SLC7A5SLC1A3SLC1A2SLC1A1USP2
SCHEMBL28153656 0.89 SLC7A5 (0.53) SLC7A5SLC1A3SLC1A2SLC1A1USP2
SCHEMBL3930054 0.86 SLC7A5 (0.50) SLC7A5SLC1A3SLC1A2SLC1A1USP2
SCHEMBL5326967 0.84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024128542-A1 CUTTING OIL COMPOSITION 와이씨켐 주식회사 2024-06-20 WO disclosed
US-11529342-B2 Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) 2022-12-20 US disclosed
EP-3006023-B1 SORBIC ACID AND DERIVATIVES THEREOF TO ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) 2019-06-26 EP disclosed
US-20190151301-A1 SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) 2019-05-23 US disclosed
EP-3006024-B1 BENZOIC ACID OR SALTS THEREOF TO ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) 2019-03-20 EP disclosed
US-10149845-B2 Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) 2018-12-11 US disclosed
US-10039730-B2 Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) 2018-08-07 US disclosed
US-20170189358-A1 SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) 2017-07-06 US disclosed
US-20170181989-A1 SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) 2017-06-29 US disclosed
US-9675604-B2 Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) 2017-06-13 US disclosed
EP-2269979-B1 DIAMINO ACID DERIVATIVE STARTING MATERIAL, MANUFACTURING METHOD THEREOF, AND DIAMINO ACID DERIVATIVE MANUFACTURING METHOD JAPAN SCIENCE & TECH AGENCY (JP) 2014-04-16 EP disclosed
US-20140012016-A1 DIAMINO ACID DERIVATIVE STARTING MATERIAL, MANUFACTURING METHOD THEREOF, AND DIAMINO ACID DERIVATIVE MANUFACTURING METHOD JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2014-01-09 US disclosed
US-8563765-B2 Diamino acid derivative starting material, manufacturing method thereof, and diamino acid derivative manufacturing method JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2013-10-22 US disclosed
US-20110071310-A1 DIAMINO ACID DERIVATIVE STARTING MATERIAL, MANUFACTURING METHOD THEREOF, AND DIAMINO ACID DERIVATIVE MANUFACTURING METHOD JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2011-03-24 US disclosed
EP-2269979-A1 DIAMINO ACID DERIVATIVE STARTING MATERIAL, MANUFACTURING METHOD THEREOF, AND DIAMINO ACID DERIVATIVE MANUFACTURING METHOD Japan Science and Technology Agency (JP) 2011-01-05 EP disclosed
US-20100189818-A1 SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) 2010-07-29 US disclosed
JP-2005255610-A METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOASPARTIC ACID DERIVATIVE NAGASE & CO LTD 2005-09-22 JP disclosed
CN-1568370-A treatment of central nervous system disorders with D-amino acid oxidase and D-aspartate oxidase antagonists GENSET SA (FR) 2005-01-19 CN disclosed
US-20030185754-A1 Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists GENSET, S.A. (FR) 2003-10-02 US disclosed
US-20030166554-A1 Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists GENSET, S.A. (FR) 2003-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140012016-A1 DIAMINO ACID DERIVATIVE STARTING MATERIAL, MANUFACTURING METHOD THEREOF, AND DIAMINO ACID DERIVATIVE MANUFACTURING METHOD DAO, DDC, DCTD SLC7A5 736/4885SLC1A3 744/4885SLC1A2 587/4885
US-20110071310-A1 DIAMINO ACID DERIVATIVE STARTING MATERIAL, MANUFACTURING METHOD THEREOF, AND DIAMINO ACID DERIVATIVE MANUFACTURING METHOD DAO, DDC, DCTD SLC7A5 736/4885SLC1A3 744/4885SLC1A2 587/4885
US-20030185754-A1 Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists DDO, DAO, XDH SLC7A5 262/4885SLC1A3 46/4885SLC1A2 12/4885
US-20030166554-A1 Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists DDO, DAO, XDH SLC7A5 262/4885SLC1A3 46/4885SLC1A2 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.